Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV - some considerations Reply

被引：0
|
作者：
Canini, Laetitia [1 ]
Guedj, Jeremie [2 ]
Perelson, Alan S. [3 ]
机构：
[1] Univ Edinburgh, Ctr Immun Infect & Evolut, Edinburgh, Midlothian, Scotland
[2] INSERM, IAME, UMR 1137, F-75018 Paris, France
[3] Los Alamos Natl Lab, Theoret Biol & Biophys Grp, Los Alamos, NM 87544 USA
来源：
ANTIVIRAL THERAPY | 2016年 / 21卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：648 / 649
页数：2
相关论文
共 13 条
  • [1] Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV - some considerations
    Srinivas, Nuggehally R.
    ANTIVIRAL THERAPY, 2016, 21 (07) : 647 - 648
  • [2] A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV
    Canini, Laetitia
    Chatterjee, Anushree
    Guedj, Jeremie
    Lemenuel-Diot, Annabelle
    Brennan, Barbara
    Smith, Patrick F.
    Perelson, Alan S.
    ANTIVIRAL THERAPY, 2015, 20 (05) : 469 - 477
  • [3] A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor
    Canini, Laetitia
    Lemenuel-Diot, Annabelle
    Brennan, Barbara J.
    Smith, Patrick F.
    Perelson, Alan S.
    ANTIVIRAL THERAPY, 2018, 23 (04) : 353 - 361
  • [4] Some Considerations in Treating Malignant Head and Neck Paragangliomas Reply
    McCrary, Hilary C.
    Cannon, Richard B.
    Buchmann, Luke O.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2020, 146 (02) : 210 - +
  • [5] Pharmacokinetic considerations for the use of the ovine model in cocaine research - Reply
    Bernards, CM
    Cullen, BF
    ANESTHESIOLOGY, 1997, 86 (03) : 747 - 747
  • [6] IDENTIFICATION OF A DUAL MECHANISM OF ACTION (MOA) FOR DANOPREVIR (DNV), A PROTEASE INHIBITOR CURRENTLY IN PHASE II, USING A MECHANISTIC VIRAL KINETIC MODEL
    Lemenuel-Diot, Annabelle
    Levi, Micha
    Shulman, Nancy
    Frey, Nicolas
    HEPATOLOGY, 2011, 54 : 548A - 548A
  • [7] Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C
    Wang, He-chuan
    Ren, Yu-peng
    Qiu, Yue
    Zheng, Jenny
    Li, Gai-ling
    Hu, Chuan-pu
    Zhou, Tian-yan
    Lu, Wei
    Li, Liang
    ACTA PHARMACOLOGICA SINICA, 2018, 39 (01) : 140 - 153
  • [8] Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C
    He-chuan Wang
    Yu-peng Ren
    Yue Qiu
    Jenny Zheng
    Gai-ling Li
    Chuan-pu Hu
    Tian-yan Zhou
    Wei Lu
    Liang Li
    Acta Pharmacologica Sinica, 2018, 39 : 140 - 153
  • [9] SOME STATISTICAL CONSIDERATIONS IN ESTIMATING A DISEASE PROGRESSION MODEL FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    Exuzides, A.
    Colby, C.
    Briggs, A.
    Riseborough, N.
    Baker, T. M.
    Ismaila, A.
    VALUE IN HEALTH, 2014, 17 (03) : A183 - A183
  • [10] Some Statistical Considerations in Estimating a Disease Progression Model for Chronic Obstructive Pulmonary Disease (COPD)
    Exuzides, Alex
    Colby, Chris
    Briggs, Andrew H.
    Riseborough, Nancy
    Baker, Timothy
    Ismaila, Afisi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 624 - 625
12